StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for PBH yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-19 | $46.46 | $46.44 | -0.04% | 0.9M |
| 05-20 | $46.13 | $47.19 | +2.30% | 0.6M |
| 05-21 | $46.71 | $48.23 | +3.25% | 0.6M |
| 05-22 | $48.19 | $48.00 | -0.39% | 0.9M |
| 05-26 | $47.60 | $48.02 | +0.88% | 0.9M |
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Annual 2026 2026-03-31 | Q4 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $1.09B | $807.09M | $523.64M | $249.53M |
Operating Income | $309.41M | $233.92M | $151.43M | $71.76M |
Net Income | $190.30M | $136.37M | $89.68M | $47.47M |
EPS (Diluted) | $3.91 | $2.78 | $1.81 | $0.95 |
Total Assets | $3.49B | $3.49B | $3.44B | $3.43B |
Total Liabilities | $1.61B | $1.67B | $1.62B | $1.58B |
Cash & Equivalents | $63.87M | $62.37M | $119.11M | $139.50M |
Free Cash Flow OCF − CapEx | $246.45M | $208.82M | $133.56M | $78.17M |
Shares Outstanding | 48.72M | 49.06M | 49.55M | 49.83M |